Pharmas & Biotechs
WHY EXTRACELLULAR VESICLES?
Extracellular vesicles have a great potential for biomarker discovery as illustrated by the significant number of publications across many indications, including but not limited to oncology, neurodegenerative diseases, cardiovascular and metabolic diseases. Typical applications are pharmacodynamic markers, predictive markers to support precision medicine and monitoring markers to assess efficacy or to detect residual disease / recurrence. Extracellular vesicles are often highly compatible with liquid biopsy, lowering the burden requested to participating subjects regarding the biosamples.
EMPOWERING AND DIFFERENTIATING YOUR CLINICAL PROGRAMS WITH INNOVATIVE MARKERS
Although other technologies such as circulating tumor DNA are available in the field of liquid biopsy, extracellular vesicles show some unique features that might allow your clinical trials to differentiate from competing compounds. In pancreas cancer for instance, one of the most sensitive and specific means to detect tumors is based on extracellular vesicles [Ref]. In neurodegenerative disease, EVbiome has been first to detect disease-associated prions from the blood of patients with sporadic Creutzfeld-Jacob disease. If your translational budget allows it, you might want to explore innovative approaches such as extracellular vesicles that might add significant values to your clinical trials.
PRACTICAL EXAMPLE OF PARTNERSHIP
The typical setting for a partnership is that we support exploratory endpoints of your clinical trials. We might receive frozen plasma from the participants and perform biomarker discovery and validation. You will receive a report with the complete set of data and analysis performed with state- of-the-art bioinformatics. In oncology, we generally work with 100 microliters of plasma. The final volume required will depend on the analyses requested, but generally speaking, the analysis of extracellular vesicles uses a limited amount of biofluid.